To date, three HDAC inhibitors have been approved by the FDA for the treatments of CTCL (vorinostat (SAHA) and romidepsin (Istodax)) and peripheral T-cell lymphoma (belinostat (Beleodaq) and romidepsin),128 and are being further evaluated for their potential as anticancer agents – alone and in combination, in haematological malignancies and solid tumours. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.